STRO - Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

2024-04-05 18:31:56 ET

Summary

• Ipsen S.A. is a pharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of commercial drug products.
• The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m.
• Ipsen typically acquires relatively de-risked drug candidates in later stage clinical studies, but last week announced a deal with Sutro Biopharma, Inc. to develop a pre-clinical antibody drug candidate.
• The deal pays $90m to Sutro - which has an ADC of its own in a registrational study in ovarian cancer.
• The deal seems to suit both parties, who have intriguing exposure to an explosive ADC market in oncology. Ipsen offers a more de-risked opportunity, Sutro explosive growth potential with a higher level of risk.

Investment Overview

Ipsen S.A. ( IPSEY , IPSEF) is a Paris, France-headquartered Pharmaceutical company focused on oncology, rare disease and neuroscience. The company's business is built upon partnering with other biotech and pharma companies developing new drugs. According to Ipsen's website:

Since 2020, Ipsen has brought in over 20-best- or first-in class programs across our pipeline at every stage of development and plans are in place to acquire more. We invest in opportunities in challenging disease areas to better address challenges faced by the community.

For further details see: